Introduction
The incidence of oesophageal adenocarcinoma has increased rapidly in the western world over the last two decades (Pohl and Welch, 2005) . The 5-year survival rate is an abysmal 13% because the majority of patients present with locally advanced disease (Medical Research Council Oesophageal Cancer Working (MRCOCW) Group, 2002) . Since most oesophageal adenocarcinomas arise on the background of Barrett's metaplasia, which gradually progresses to carcinoma through a metaplasia-dysplasia-carcinoma sequence, this provides the opportunity to intervene at an early stage. A greater understanding of the pathogenesis of Barrett's associated cancer is required to develop effective chemopreventive strategies.
An association between vitamin A (retinoic acid, RA) deficiency and carcinogenesis has been known since the 1920s when vitamin A-deficient rats were observed to develop squamous metaplasia of the lung mimicking the changes caused by smoking (Wolbach and Howe, 1925) . Since then, a number of experimental animal models have demonstrated that vitamin A deficiency is associated with increased susceptibility to carcinogenesis (Bertram, 1993; Avidan et al., 2002) . In humans, epidemiological data have demonstrated a relationship between low levels of serum b-carotene and vitamin A intake and the risk of various human cancers including cervical pre-cancerous lesions (Saffiotti et al., 1967; Wald et al., 1980; Smith and Waller, 1991) . These effects have been shown to occur through defects in DNA repair (Webster et al., 1996) , increased cell proliferation (Reifen et al., 1998) and a number of genotoxic events (Klamt et al., 2003) .
Disruption of normal retinoid signalling may occur as a result of reduced expression of retinoid receptors, reduced transcriptional responses of RA target genes and increased RA metabolism (Freemantle et al., 2003) . A member of the cytochrome P450 family, CYP26A1, has recently been identified as a major RA-catabolizing enzyme, which converts RA to biologically inactive hydroxylated retinoid derivatives (Niederreither et al., 2002) . CYP26A1 has been shown to be upregulated in human familial adenomatous polyposis adenomas, sporadic colon cancers and primary ovarian cancer (Downie et al., 2005; Shelton et al., 2006) . Furthermore, the pattern of retinoid gene expression, including CYP26A1, has been shown to correlate with retinoid sensitivity in a panel of breast and lung cancer cell lines (Liu et al., 2005) .
Apart from the connection between RA deficiency states and cancer, there are several reasons why CYP26A1 might be implicated in Barrett's oesophagus and associated carcinogenesis. First, Barrett's oesophagus may be considered as an abnormal re-activation of embryonic patterning since the oesophagus undergoes a columnar to squamous transition at 18 weeks gestation. CYP26A1 is necessary for the establishment of the anterior-posterior axis in embryogenesis (Abu-Abed et al., 1998), and we have recently shown that alterations in RA concentration levels can affect differentiation of human oesophagus ex vivo (Chang et al., 2007) . Second, chronic exposure to duodeno-gastro-oesophageal refluxate is the only well-established risk factor for Barrett's carcinogenesis (Winters et al., 1987) , and the bile acid lithocholic acid (LCA) has recently been demonstrated to compete efficiently with 9-cis-RA for the retinoid X receptor (RXR)-binding sites on the promoter region of the CYP26A1 gene (Radominska-Pandya and Chen, 2002) .
Therefore, the specific aims of this study were to determine the relative levels of RA and CYP26A1 expression in neoplastic compared with non-neoplastic Barrett's cells in vitro and in vivo, to evaluate the effects of LCA on CYP26A1 expression and to examine the molecular and functional effects of CYP26A1 overexpression using an in vitro model system.
Results
Decreased retinoid levels in neoplastic relative to non-dysplastic Barrett's cells First, we determined the relative levels of RA in Barrett's carcinogenesis. Barrett's telomerase-immortalized cell lines were treated with 10 À7 M RA over 24 h and then examined for RA levels using retinoic acid response element (RARE) reporter cells. The results demonstrated that non-dysplastic Barrett's cell lines, BAR (7.16 Â 10 À11 ± 2.20 Â 10 À11 M) and QhTERT (2.91 Â 10 À11 ± 1.38 Â 10 À11 M), had higher retinoid levels, compared to dysplastic cell lines, ChTERT (1.51 Â 10 À11 ± 0.09 Â 10 À11 M),
GohTERT
(6.73 Â 10 À12 ± 4.29 Â 10 À12 M) and GihTERT (2.40 Â 10 À12 ± 1.53 Â 10
Po0.0001; Figure 1a ), and transformed normal oesophagus cell lines Het1a (2.43 Â 10 À12 ±1.28 Â 10
and NES (1.60 Â 10 À12 ± 0.32 Â 10 À12 M). We confirmed the in vivo relevance of these changes using oesophageal tissues from patients with non-dysplastic Barrett's and adenocarcinoma. Specifically, the mean retinoid level in Barrett's oesophageal biopsies (5.92 Â 10 À11 ± 1.28 Â 10 À11 M) was increased 13-fold compared to normal oesophagus (1.94 Â 10 À12 ± 0.73 Â 10 À12 M) and 5.5-fold compared to adenocarcinoma biopsies (1.04 Â 10 À11 ± 0.9 Â 10 À11 M, P ¼ 0.033; Figure 1b ).
Increased CYP26A1 gene expression in Barrett's carcinogenesis Cellular retinoid activity is modulated via the balance between production and metabolism. Measurement of the expression levels of the main RA-producing enzyme RALDH2 in Barrett's cell lines and tissues did not reveal any differences (data not shown). Therefore, we next examined the expression levels of the main catabolizing enzyme, CYP26A1. The constitutive expression of CYP26A1 in all the cell lines is very low, but detectable by real-time PCR. We demonstrated that CYP26A1 mRNA transcript levels were induced by RA in the GihTERT cell line in a dose-dependent manner (10 À5 -10 À10 M all-trans retinoic acid (ATRA)), (data not shown) and therefore, 10 À8 M was chosen for subsequent experiments. Across the panel of cell lines, RA led to a significant induction of this gene, which was most marked in the dysplastic cell lines (GohTERT, ChTERT and GihTERT) compared to the non-dysplastic Figure 1 Retinoic acid concentration in a Barrett's oesophagus cells and tissues. Cell lines representative of Barrett's carcinogenic sequence (a) or Barrett's metaplasia (BE) and adenocarcinoma (Ca) patients (b) were cultured for 24 and 18 h respectively with 100 nM retinal in serum-free medium. The resultant medium (100 ml) from cell or biopsy culture was then added to a 96-well plate containing 3T3 RARE-SEAP reporter cells and incubated for 24 h. SEAP concentration in the medium was determined by Great EscApe detection kit. Relative RA levels were calculated by comparison with a standard curve using serial RA concentrations and then adjusted for the protein content of the cells. In panel a, for each cell line, three biological replicates (each with three technical replicates) were performed. For panel b, the level of RA was determined in triplicate in each biopsy sample (***Po0.0001 and **Po0.01).
Barrett's cell lines, BAR and QhTERT (Po0.01; Figure 2a ). Measurement of the promoter activity, using a luciferase reporter vector containing a 354-bp proximal 5 0 sequence of CYP26A1, revealed an increased reporter activity in dysplastic cell lines consistent with the expression levels (Po0.01; Figure 2b ). In patient biopsies, real-time PCR data revealed a significant upregulation of CYP26A1 in adenocarcinoma compared with non-dysplastic Barrett's tissues (Po0.01; Figure 2c ). These results were obtained in the absence of any exogenous ATRA and reflect basal transcript levels.
In the light of this in vivo data, we next determined the level of protein expression in tissue sections comprising each stage of the metaplasia-dysplasia-adenocarcinoma. A western blot was performed with affinity-purified anti-CYP26A1 antibody alone and following preincubation with CYP26A1 peptide to ensure antibody specificity ( Figure 3a ). The degree of immunostaining for Barrett's tissues without dysplasia (Figures 3b, c, 4a and b) and with low-grade dysplasia (Figures 3b, c, 4c and d) was generally low. Where staining was present, it was confined to the deep glands (black arrow) and the lamina propria (red arrow). In contrast, there was strong immunostaining in samples containing highgrade dysplasia (Figures 3b, 4e and g ) and adenocarcinoma (Figures 3b, 4h and i) with a shift towards increased expression in the epithelial compartment and reduced expression in the lamina propria (Figure 3c ). The staining was localized primarily to dysplastic epithelial cells within the glands (Figure 4g ) compared with the surface (Figure 4f ). The intensity of CYP26A1 staining was also seen to increase in the epithelial compartment throughout the metaplasia-dysplasiaadenocarcinoma sequence (Figure 3b ). Together, these in vivo and in vitro data suggest that CYP26A1 gene expression is upregulated during the carcinogenic sequence of Barrett's oesophagus.
Lithocholic acid and RA synergistically enhance the expression of CYP26A1 Since duodeno-gastro-oesophageal reflux is causally implicated in Barrett's carcinogenesis and since LCA competes with RA for the RXR-binding site, we examined the effect of the secondary bile acid LCA on CYP26A1 gene expression. LCA (15 mM) alone significantly increased its expression in GihTERT cells (Po0.05). ATRA and LCA in combination resulted in a two-and threefold enhancement of CYP26A1 gene expression for GihTERT at 10 À7 M of RA and Goh-TERT respectively, compared to addition of ATRA alone (Po0.05; Figures 5a and b).
Overexpression of CYP26A1 in Barrett's cells enhances cell proliferation and survival
To investigate the functional role of CYP26A1 overexpression, we used GihTERT since its expression levels were most profoundly induced by RA in these cells and their transfection efficiency is good. Two stable cell lines were established, using a vector for pCEP4-CYP26A1 and a pCEP4 empty vector, (Figure 6a ). To examine the molecular mechanisms by which CYP26A1 might be (TNF, FAS, FASLG) . In addition, differentiation of cell cycle regulators, cyclindependent kinase inhibitors (CDKN1A, CDKN1B, CDKN1C, CDKN2A) and retinoid-binding proteins (RBPs) were also repressed. Oncogenes, in particular epidermal growth factor receptor (EGFR) and c-Myc, were upregulated (Figure 6b ), and this was confirmed by real-time PCR (Figure 6c ). In addition to the global analysis of genes involved in cell signalling, we also performed real-time PCR for matrix metalloproteinases (MMPs) and tissue inhibitor metalloproteinases (TIMPs) in view of their known role in invasion. Out of the genes examined (MMP-1, -2, -3, -7, -9, -10, -14 and TIMP-1, -2, -3), the MMP-3 gene was found to be significantly upregulated (P ¼ 0.003), and TIMP-1 and -2 were downregulated (P ¼ 0.005 and 0.01, respectively) in GihTERT/pCEP4-CYP26A1 cells, relative to GihTERT/pCEP4 control cells (Figure 6d ).
In view of the gene expression patterns that favoured cell survival and invasion, we performed functional assays for these parameters. These CYP26A1-overexpressing cells showed enhanced cell growth, compared to empty vector-transfected cells in an in vitro MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (P ¼ 0.002, Figure 7a ). This difference was abolished by adding 2 mM ketoconazole, a pancytochrome P450 inhibitor (P ¼ 0.008; Figure 7a ). Flow cytometric analysis provided further evidence for increased proliferation since GihTERT/pCEP4-CYP26A1 cells exhibited a higher percentage of cells in the S and G 2 M phase (S ¼ 17.1%, G 2 M ¼ 24.24%) compared to control GihTERT/pCEP4 cells (S ¼ 10.19%, G 2 M ¼ 18.1%). In addition, GihTERT/ pCEP4-CYP26A1 cells were more invasive in vitro than control cells (Po0.001), and this invasive behaviour was inhibited with ketoconazole (Po0.01; Figure 7b ).
Discussion
We have demonstrated decreased RA levels and increased expression of CYP26A1 in Barrett's associated dysplasia and adenocarcinoma in vitro and in vivo. LCA, a component of refluxate, and RA synergistically enhance the expression of CYP26A1. Overexpression of CYP26A1 led to upregulation of MMP-3, TIMP-1, -2 and oncogenes EGFR and c-Myc and altered the biological behaviour of Barrett's GihTERT cells leading to enhanced proliferation and invasion.
CYP26A1 was recently cloned and is believed to be responsible for the 4-hydroxylation of ATRA, which in turn diminishes RA signalling activity. In a mouse model with mutated RALDH2 and CYP26, the hydroxylated derivates of CYP26 were shown to be biologically inactive (Niederreither et al., 2002) . We have recently shown that manipulation of RA concentrations has profound effects on differentiation status ex vivo (Chang et al., 2007) . However, this analysis was confined to non-dysplastic Barrett's oesophagus. Very little work has been performed in Barrett's associated adenocarcinoma to determine the availability of RA and whether its signalling is intact. Altered expression of retinoic acid receptors (RAR) a and g as well as all three RXR has been described (Lord et al., 2001; Brabender et al., 2004) ; however, the molecular mechanism and functional consequences of these alterations have not been investigated. Here we focused on the CYP26A1 enzyme; however, it is also possible that reduced RA levels are due to aberrant expression of cellular retinalbinding protein or lecithin:retinal acyltransferase. These two proteins mediate the esterification of retinal to retinylester, the hepatic storage form of retinal. The integrity of the other signalling components should be investigated further; however, our data suggest that CYP26A1 overexpression is at least partially responsible for the relative RA deficiency in adenocarcinoma compared to Barrett's metaplasia.
Expression of CYP26A1 may be inducible by RA or RAR, RXR agonists. Two putative RARE sites exist on the proximal (À132) and distal (À2090) 5 0 region of this gene, which have been shown to work cooperatively (Loudig et al., 2005) . Analysis suggests that there are potential DR5 RARE-or RXR-binding sites noted around the 2K 5 0 region. LCA has recently been demonstrated to compete efficiently with 9-cis-RA for the RXR retinoid-binding site. Here we have shown that LCA can activate RA signalling in reporter cells and induce CYP26A1 expression when acting synergistically with RA. Since only modest CYP26A1 induction was observed with LCA alone, the enhancement might occur through the RARE. Hence, because there is repetitive exposure of the Barrett's mucosa to refluxate containing bile acids in vivo, it is possible that CYP26A1 expression may be induced even under relatively low concentrations of RA. It is also possible that inflammation may play a role, since there are also nuclear factor B-binding sites in the promoter of CYP26A1. Further work is required to determine how CYP26A1 gene is regulated in Barrett's metaplasia and associated dysplasia.
Overexpression of CYP26A1 also results in an increased proliferation index in keeping with data showing that this gene confers a growth advantage (Osanai and Petkovich, 2005) . In view of the multiple signalling pathways, which might affect cell proliferation, we used an array approach to identify candidates. The pattern of gene expression identified included apoptosis-regulating genes, repression of tumour suppressor genes, de-regulation of cell cycle and activation of growth factor (EGFR) and c-Myc genes. These alterations are similar to the molecular events reported in Barrett's carcinogenesis (reviewed in Bax et al., 2005) . Increased retinoid activity has been linked to an abrogation of EGFR signalling (Sah et al., 2002) . In addition, c-Myc expression was also reduced in retinoidtreated human leukaemia cells (Yung, 2004) . Therefore, it is perhaps not surprising that CYP26A1 overexpression increases expression of these oncogenes.
The in vitro matrigel assay demonstrated that dysplastic Barrett's GihTERT cells overexpressing the CYP26A1 gene had increased capacity for invasion, which was associated with the upregulation of MMP-3 and downregulation of TIMP-1 and -3. RA has been documented to affect invasion by modulating the TIMPs or MMPs in many instances (Schoenermark et al., 1999; Bigg et al., 2000) . The conclusions drawn Role of CYP26A1 in Barrett's carcinogenesis C-L Chang et al from these experiments must be cautious since overexpressing genes of interest can lead to nonspecific effects. However, due to the low basal CYP26A1 transcript levels in cell lines, knockdown experiments were not possible. The abrogation of the functional effects of CYP26A1 overexpression by ketoconazole suggests that the effects are mediated via the cytochrome P450 system, but in future more specific antagonists, which are not yet commercially available, would add further weight.
The role of RA in cell differentiation, growth and apoptosis has provided the rationale to use RA as a chemoprevention and chemotherapeutic agent in Barrett's oesophagus (Hormi-Carver et al., 2007) and other tumour types. Hence, clinical remission in acute promyelocytic leukaemia patients who respond to RA therapy correlates with terminal differentiation of leukaemic blasts. Similarly, in vitro inhibition of CYP26 leads to an increase in differentiation, decrease in proliferation, cell adhesion and metastatic potential. This has led to the suggestion of a possible chemoprevention role of using specific CYP26 inhibitors (Wouters et al., 1992; Van Heusden et al., 2002) . In addition, RA metabolism-blocking agents lead to a reduction of tumour size in mouse xenograft models (Patel et al., 2004) .
In conclusion, we have demonstrated increased expression of CYP26A1 in Barrett's carcinogenesis and investigated the functional significance of this gene in oesophageal adenocarcinoma including proliferation and invasion. These data suggest that the potential benefit of RA metabolism-blocking agents in cancer therapy deserves further study.
Materials and methods
All the work in this study was performed on human material (biopsy samples or cell lines).
Patient samples
Biopsy samples were obtained from patients having endoscopy at Addenbrooke's Hospital NHS Trust, following approval by the local research ethics committee. Barrett's oesophageal samples were obtained from surveillance endoscopies and oesophageal squamous tissue specimens from diagnostic endoscopy procedures in patients who had an endoscopically and histopathologically normal squamous oesophagus. Paired research samples were taken together with samples for routine pathological examination. The research samples were either snap frozen in liquid nitrogen and stored at À80 1C or stored in holding medium for organ culture and processed within 6 h. For immunohistochemistry, samples of Barrett's oesophagus with varying degrees of dysplasia and adenocarcinomas as well as samples of normal squamous epithelium were selected from the Addenbrooke's archive.
Cell lines
A panel of hTERT-immortalized Barrett's cell lines, which were derived from well-characterized patients with different degrees of dysplasia within Barrett's oesophagus, was used to determine the retinoid activity at different stages of the metaplasia-dysplasia sequence. The hTERT-immortalized non-dysplastic Barrett's cell line BAR (gifts from Rhonda F Souza, University of Texas Southwestern Medical Center, TX, USA) was grown on a 3T3 sorry feeder layer in KBM-2 (Cambrex, UK) medium and supplemented as previously described (Hormi-Carver et al., 2007) . In addition, an hTERTimmortalized non-dysplastic cell line, QhTERT (CP-A), and three dysplastic cell lines, ChTERT (CP-B), GohTERT (CP-D) and GihTERT (CP-D) (gifts from P Rabinovich, University of Washington, WA, USA), were maintained in MCDB 153 medium (Sigma, St Louis, MO, USA) and supplemented as described previously (Palanca-Wessels et al., 2003) .
Reporter cells and retinoic acid levels
Cell lines and biopsies in organ culture were maintained in serum-free medium containing 100 nM retinal for 24 h (Sigma). RA levels in the medium were determined using a reporter cell system. For this, Swiss 3T3 cells were transfected with 1.2 mg of pRARE-TA-SEAP (Clontech, Mountain View, CA, USA) and 0.2 mg of pIres-puro (Clontech). Puromycin was used to select cells stably expressing the reporter and after 24 h, the phosphatase activity was quantified using a Great EscAPe SEAP detection kit (BD Bioscience, San Jose, CA, USA). Relative RA content in the medium was calculated by comparison with a standard curve (serial RA concentrations À7 and 10 À8 M RA alone or a combination of LCA and RA. After 6 h, total RNA was extracted and CYP26A1 gene expression was measured by real-time (RT)-PCR (*Po0.05 and **Po0.01). LCA, lithocholic acid; RA, retinoic acid.
À6
-10 À12 M) and adjusted for protein content according to the bicinchoninic acid protein assay using a commercially available kit (Pierce, Rockford, IL, USA).
Expression and reporter constructs
To clone the full-length CYP26A1, GihTERT cells were treated with 100 nM ATRA and then RNA was extracted using Trizol (Invitrogen, Paisley, UK). Reverse transcriptase-PCR (RT-PCR) was performed using the forward primer 5 0 -CCG CTCGAGGATGAAGCGCAGGAAATACG-3 0 , containing Xho 1 restriction site and the reverse primer 5 0 -CGGG ATCCTCAAGCTCATCAGATTTCCC-3 0 , containing the BamH1 site by Vent (NEB, UK). The PCR fragment was digested and cloned in-frame into the eukaryotic expression vector pCEP4 (Invitrogen) and confirmation was obtained by sequencing. pCEP4 is an episomal mammalian vector containing the Epstein-Barr virus replication origin (oriP) and nuclear antigen (EBNA-1 gene), to permit extrachromosomal replication in humans. Thus in our experiment, we used pooled transfected cells selected by hygromycin B, rather than single clones. The CYP26A1 promoter reporter was constructed in two steps. PCR cloning of a 2K fragment of the CYP26A1 promoter sequence was performed using Pfu polymerase Figure 6 Validation of the membrane array data. The expression of CYP26A1 (green) was confirmed by immunofluorescence in GihTERT cells stably transfected with pCEP4 empty vector or pCEP4-CYP26A1. The nuclei are labelled with DAPI (blue (a)). The expression pattern of cells overexpressing CYP26A1 was analysed using a gene expression array membrane. This assay was performed in duplicate and results for the two repeats are represented in blue and red (b). Validation of EGFR and c-Myc genes (c) as well as MMP and TIMP genes by real-time PCR (d) from RNA extracted from sub-confluent GihTERT cells stably expressing the CYP26A1 gene or control. DC(t) is the relative cycle threshold of target gene to GAPDH determined from amplification curve in real-time PCR. DAPI, 4',6-diamidino-2-phenylindole; EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; TIMP, tissue inhibitor metalloproteinase.
(Promega, Southampton, UK) and genomic DNA prepared from GihTERT cells. The forward primer was 5 0 -GGGG TACCCAGAGTTCACTCGGATGTCACG-3 0 containing the Kpn1 site and the reverse primer was 5 0 -TACCATCTGC AAGGTTTCCC-3 0 . The PCR fragment was digested by Kpn1 and Nco1, cloned into pGL3-basic vector (Promega, Madison, WI, USA) and confirmed by sequencing. The vector was then digested with Kpn1, EcoR1 and Klenow enzymes. The pGL3-CYP26A1 promoter (354 bp) was obtained by re-ligation and sequencing confirmation was performed.
Immunohistochemistry and scoring
Archival blocks of tissue samples from Barrett's oesophagus (n ¼ 10), low-grade dysplasia (n ¼ 10), high grade dysplasia (n ¼ 10) and adenocarcinoma (n ¼ 10) patients were deparaffinized in xylene and then rehydrated through alcohol solutions and water. Antigen retrieval was performed by pressure cooking of samples for 3 min in 0.01 M tri-sodium citrate (VWR International, Poole, England) at pH 6.0. Nonspecific binding was blocked using 10% normal goat serum (Vector Labs, Burlingame, CA, USA) and 10% bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA) for 30 min at room temperature. Staining was performed using the DakoCytomation EnVision þ System (DakoCytomation Ltd, Ely, UK) staining kit according to the manufacturer's instructions. The primary antibody, a rabbit polyclonal antibody raised against the human C-terminal 18-amino peptide of CYP26A1, which is specific for the A1 isoform (Alpha Diagnostic International, San Antonio, TX, USA), was diluted in tris buffered saline/ Tween 0.05% containing 1% bovine serum albumin and incubated for 1 h at room temperature. A negative control was performed by omission of the primary antibody. Sections were then counter stained with haematoxylin and mounted. Scoring of immuno-positive cells for CYP26A1 was done separately for the epithelial and lamina propria compartments. CYP26A1 staining was scored according to the overall distribution (0 ¼ none, 1 ¼ o25%, 2 ¼ 25-50%, 3 ¼ 50-75% 4 ¼ >75% of cells stained) and intensity of staining (0 ¼ negative, 1 ¼ weak, 2 ¼ moderate, 3 ¼ strong staining).
RA and lithocholic acid stimulation
Fully confluent 3T3 RA reporter cells were cultured in a 96-well format in serum-free medium for 24 h with either 10 À8 -10 À7 M of ATRA (Sigma-Aldrich, Dorset, UK), or LCA (Sigma) at 5, 10 and 15 mM or a combination of RA and LCA over the same concentration range.
Serum-free medium with the same concentration of ethanol as vehicle served as a control. After 1 h of stimulation, the cells were washed with phosphate-buffered saline and cultured in 100 ml serum-free medium for 12 h. Secreted alkaline phosphatase (SEAP) activity in the medium was quantified using the SEAP detection kit. For detecting the LCA-enhanced expression of CYP26A1 gene, two immortalized Barrett's cell lines, GihTERT and GohTERT, were cultured to reach confluency and then stimulated with LCA (15 mM) alone, RA (10 À7 and 10 À8 M) or a combination of LCA and RA. After 6 h, total RNA was extracted and CYP26A1 gene expression was measured by real-time PCR.
MTT assay
GihTERT/pCEP and GihTERT/pCEP-CYP cells were cultured in 24-well plates at a density of 5 Â 10 4 cells per well for up to 4 days. The pCEP-CYP cells were also cultured with 2 mM of Ketoconazole (Sigma-Aldrich). The MTT assay was performed in quadruplicate for each time point according to the manufacturer's instructions (Sigma-Aldrich, Paisley, UK). The absorbance was measured spectrophotometrically at a wavelength of 570 nm from which the background was subtracted.
Determination of cell cycle distribution A total of 3 Â 10 6 cells were grown for 24 h as a monolayer and then trypsinized, suspended in culture medium, centrifuged at 150 g for 10 min, and fixed in 70% ethanol overnight. The fixed cells were centrifuged again, and the cell pellet was resuspended in propidium iodide (0.2 mg ml
À1
; Sigma) and incubated for 30 min at room temperature. Cells were passed through a 70 mM cell strainer (BD Biosciences, Oxford, UK). DNA content was analysed by fluorescence-associated cell sorting using the BD LSR1 flow cytometer (BD Biosciences). Data were captured using Cell Quest software (BD Biosciences) and analysed with ModFitLT software (Verity Software, Topsham, ME, USA).
Real-time RT-PCR
Total RNA from cells or tissues was extracted by using Trizol (Invitrogen). Two micrograms of RNA was reverse transcribed .05 between untreated and treated G1hTert/pCEP4-CYP; **Po0.001 between untreated G1hTert/pCEP4-CYP and Gih-TERT/pCEP4). (b) Invasion assay in GihTERT/pCEP4 and GihTERT/pCEP4-CYP cells cultured in Matrigel-coated inserts in a transwell system in 0.5% fetal bovine serum medium, with 5% fetal bovine serum medium in the bottom of chamber as chemoattractant. After 24 h, the cells migrating through the Matrigel filter were fixed and stained, and the number of cells was measured by counting the average in five randomly chosen 1 mm 2 fields (**Po0.01). MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide.
Role of CYP26A1 in Barrett's carcinogenesis C-L Chang et al using a SuperScript II reverse transcriptase kit (Invitrogen) in 20 ml of total reaction solution, and diluted into 100 ml in RNAse-free water. Each RNA sample was prepared in triplicate. The primers used are listed in Table 1 . Quantitative PCR was performed on 2 ml of cDNA with the SYBR Green JumpStart Taq Readymix (Sigma-Aldrich). PCR consisted of 40 cycles of 94 1C denaturation (10 s), 57-59 1C annealing (20 s) and extension (20 s). The cycle threshold C(t) was determined for each sample, and the average C(t) of triplicate samples was calculated. The expression of each gene relative to glyceraldehyde-3-phosphate dehydrogenases (GAPDH) was determined as DC(t). We used serial dilutions of pCEP4-CYP26A1 vector DNA as an internal control and the melting curve was constructed for each primer.
Expression array analysis RNA from GihTERT/pCEP4-CYP26A1 or GihTERT/pCEP4 stable cells was analysed using a pathway array membrane (SuperArray, Bethesda, MD, USA). mRNA was isolated using oligodT-linked magnetic bead-based purification kit (SuperArray). A total of 0.3 mg purified mRNA was reverse transcribed to cDNA probe by SuperScript II reverse transcriptase, with incorporation of Biotin-16-dUTP (Roche, Nutley, NJ, USA). Hybridization was performed following the manufacturer's protocol and the signal was detected using a chemiluminescent CDP-Star kit (SuperArray). The membranes were exposed to X-ray films, which were developed, scanned and analysed by GEArray expression analysis software (SuperArray). The experiment was performed in duplicate with independent preparation of mRNA. The data from each membrane were normalized by comparison to a panel of house-keeping genes present on the membrane (GAPDH, RPL13A, PPIA and b-actin). Gene expression in CYP26A1-expressing GihTERT cells was calculated relative to that of GihTERT control cells. The data were not analysed statistically since duplicate values are not sufficient to perform a statistical test. However, two putative overexpressed genes were confirmed by RT-PCR to validate the array data.
Matrigel invasion assay A total of 2 Â 10 4 stable GihTERT cells expressing CYP26A1 or control were plated in triplicate on cell-culture inserts of transwell chambers (Corning, Corning, NY, USA) containing 6.5-mm filters (pore size, 8 mm) and coated with 25% Matrigel. The top chamber contained 0.5% fetal bovine serum medium with 5% fetal bovine serum medium in the bottom chamber as a chemoattractant. After 24 h, the migrating cells present on the bottom part of the filters were fixed and stained, from which the percentage of invading cells was determined.
Statistics
Data are presented as the mean and the standard error of the mean. The one-way analysis of variance test was used to identify specific differences within a population followed by the t-test to identify specific differences between selected groups. Analysis was carried out using Prism v3.0 (GraphPad Software, CA, USA). A P-value o0.05 was considered significant: *Po0.05, **Po0.01 and ***Po0.0001. Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; TIMP, tissue inhibitor metalloproteinase.
